Despite 1 Major Headwind and Pricey Shares, This Stock Is Still a Buy
Supernus Pharmaceuticals' revenue mix is shifting, and it could soon have more sales on the way.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. (""Supernus" or the "Company") (NASDAQ: SUPN)....
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. (""Supernus" or the "Company") (NASDAQ: SUPN)....